Related Experiment Video
Updated: Oct 21, 2025
Creation and Maintenance of a Living Biobank - How We Do It
Published on: April 10, 2021
Tumor organoid-originated biomarkers predict immune response to PD-1 blockade
Cansu Cimen Bozkus1, Nina Bhardwaj1
1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Abstract:
Despite the demonstrated efficacy and broad applicability of checkpoint blockade, the mechanisms by which it exerts its antitumor effects are incompletely understood. A recent article in Nature Medicine describes an ex vivo platform for assessing early responses to checkpoint blockade and the properties of tumor immune contexture in correlation to clinical responses.
Insights
Researchers developed a new ex vivo platform to understand how checkpoint blockade immunotherapy works against tumors. This tool helps analyze early treatment responses and tumor immune characteristics linked to patient outcomes.
Area of Science:
- Immunology
- Oncology
- Translational Medicine
Background:
- Immune checkpoint blockade (ICB) therapy shows broad efficacy against various cancers.
- The precise mechanisms underlying ICB's antitumor effects remain incompletely understood.
- Understanding ICB mechanisms is crucial for improving patient responses and treatment strategies.
Purpose of the Study:
- To describe a novel ex vivo platform for evaluating early responses to ICB.
- To correlate tumor immune contexture properties with clinical responses to ICB.
- To advance the understanding of ICB's antitumor mechanisms.
Main Methods:
- Development and implementation of an ex vivo platform.
- Assessment of early cellular and molecular responses to ICB agents.
- Analysis of tumor immune microenvironment (TME) features.
- Correlation of ex vivo findings with patient clinical outcomes.
Main Results:
- The ex vivo platform successfully assessed early responses to ICB.
- Specific tumor immune contexture features were identified and correlated with ICB efficacy.
- The study provides insights into the biological basis of response and non-response to ICB.
Conclusions:
- The developed ex vivo platform is a valuable tool for studying ICB mechanisms.
- Characterizing tumor immune contexture is important for predicting ICB response.
- Further research using this platform can optimize ICB therapy for cancer patients.
